On the methodology of drug trials in migraine with aura

Cephalalgia

Volumn 30, Issue 9, 2010, Pages 1041-1048

  Hauge, Anne Werner ^a   Hougaard, Anders ^a   Olesen, Jes ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

aura; clinical trials; Migraine; treatment

Indexed keywords

TONABERSAT;

ANALGESIA; CLINICAL TRIAL; FAMILIAL HEMIPLEGIC MIGRAINE; HEADACHE; HEMIPLEGIC MIGRAINE; HUMAN; MIGRAINE WITH AURA; PROPHYLAXIS; REVIEW;

BENZAMIDES; BENZOPYRANS; CLINICAL TRIALS AS TOPIC; HUMANS; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 78449281289     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102409359091     Document Type: Review

References (49)

1. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. Cephalalgia 1991 ; 11: 1-12.
2. International Headache Society Committee on Clinical Trials/Schoenen J. Guidelines for trials of drug treatments in tension-type headache. Cephalalgia 1995 ; 15: 165-179.
3. Silberstein S., Tfelt-Hansen P., Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008 ; 28: 484-495.
4. Tfelt-Hansen P., Block G., Dahlof C., et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000 ; 20: 765-786.
5. Lipton RB, Micieli G., Russell D., Solomon S., Tfelt-Hansen P., Waldenlind E. Guidelines for controlled trials of drugs in cluster headache. Cephalalgia 1995 ; 15: 452-462.
6. Kangasniemi P., Andersen AR, Andersson PG, et al. Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 1987 ; 7: 231-238.
7. Hauge AW, Asghar MS, Schytz HW, Christensen K., Olesen J. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol 2009 ; 8: 718-723.
8. Jensen K., Tfelt-Hansen P., Lauritzen M., Olesen J. Clinical trial of nimodipine for single attacks of classic migraine. Cephalalgia 1985 ; 5: 125-131.
9. Bates D., Ashford E., Dawson R., et al. Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology 1994 ; 44: 1587-1592.
10. Olesen J., Diener HC, Schoenen J., Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004 ; 11: 671-677.
11. Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain 1996 ; 119 (Pt 2). 355-361.
12. Eriksen MK, Thomsen LL, Andersen I., Nazim F., Olesen J. Clinical characteristics of 362 patients with familial migraine with aura. Cephalalgia 2004 ; 24: 564-575.
13. Lampl C., Katsarava Z., Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005 ; 76: 1730-1732.
14. McArthur JC, Marek K., Pestronk A., McArthur J., Peroutka SJ Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects. Neurology 1989 ; 39: 284-286.
15. Aurora SK, Barrodale PM, McDonald SA, Jakubowski M., Burstein R. Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache 2009 ; 49: 1001-1004.
16. Olesen J., Goadsby PJ, Ramadan NM, Tfelt-Hansen P., Welch KM The headaches, 3 rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006.
17. Dahlof C., Hauge AW, Olesen J. Efficacy and safety of tonabersat, a gab-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study. Cephalalgia 2009 ; 29 (Suppl 2). 7-16.
18. Goadsby PJ, Ferrari MD, Csanyi A., Olesen J., Mills JG Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 2009 ; 29: 742-750.
19. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2 nd edn. Cephalalgia 2004 ; 24 (Suppl 1). 1-160.
20. Jones B., Lewis JA Cross-over trials versus parallel-group trials. In: Olesen J, Tfelt-Hansen P (eds) Headache treatment: trial methodology and new drugs. Philadelphia: Lippincott & Raven, 1997, p. 35-43.
21. de Vries B., Frants RR, Ferrari MD, van den Maagdenberg AM Molecular genetics of migraine. Hum Genet 2009 ; 126: 11-32.
22. Hansen JM, Thomsen LL, Marconi R., Casari G., Olesen J., Ashina M. Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. Cephalalgia 2008 ; 28: 367-375.
23. Hansen JM, Thomsen LL, Olesen J., Ashina M. Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide. Cephalalgia 2008 ; 28: 496-505.
24. Hansen JM, Thomsen LL, Olesen J., Ashina M. Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. Neurology 2008 ; 71: 841-847.
25. Kirchmann M., Thomsen LL, Olesen J. Basilar-type migraine: clinical, epidemiologic, and genetic features. Neurology 2006 ; 66: 880-886.
26. Eriksen MK, Thomsen LL, Olesen J. The Visual Aura Rating Scale (VARS) for migraine aura diagnosis. Cephalalgia 2005 ; 25: 801-810.
27. Jensen R., Brinck T., Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994 ; 44: 647-651.
28. Schrader H., Stovner LJ, Helde G., Sand T., Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001 ; 322: 19-22.
29. Gervil M., Ulrich V., Kyvik KO, Olesen J., Russell MB Migraine without aura: a population-based twin study. Ann Neurol 1999 ; 46: 606-611.
30. Ulrich V., Gervil M., Kyvik KO, Olesen J., Russell MB Evidence of a genetic factor in migraine with aura: a population-based Danish twin study. Ann Neurol 1999 ; 45: 242-246.
31. Bousser MG, Welch KM Relation between migraine and stroke. Lancet Neurol 2005 ; 4: 533-542.
32. Diener HC, Kuper M., Kurth T. Migraine-associated risks and comorbidity. J Neurol 2008 ; 255: 1290-1301. 33. Donaghy M., Chang CL, Poulter N. Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. J Neurol Neurosurg Psychiatry 2002 ; 73: 747-750.
33. Kurth T., Slomke MA, Kase CS, et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 2005 ; 64: 1020-1026.
34. Kurth T., Schurks M., Logroscino G., Buring JE Migraine frequency and risk of cardiovascular disease in women. Neurology 2009 ; 73: 581-588.
35. Oedegaard KJ, Neckelmann D., Mykletun A., et al. Migraine with and without aura: association with depression and anxiety disorder in a population-based study. The HUNT Study. Cephalalgia 2006 ; 26: 1-6.
36. Truong T., Slavin L., Kashani R., et al. Prevalence of migraine headaches in patients with congenital heart disease. Am J Cardiol 2008 ; 101: 396-400.
37. Fazekas F., Koch M., Schmidt R., et al. The prevalence of cerebral damage varies with migraine type: a MRI study. Headache 1992 ; 32: 287-291.
38. Kruit MC, van Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA 2004 ; 291: 427-434.
39. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA Infarcts in the posterior circulation territory in migraine: the population-based MRI CAMERA study. Brain 2005 ; 128: 2068-2077.
40. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA Brain stem and cerebellar hyperintense lesions in migraine. Stroke 2006 ; 37: 1109-1112.
41. Bowyer SM, Aurora KS, Moran JE, Tepley N., Welch KM Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann Neurol 2001 ; 50: 582-587.
42. Hadjikhani N., Sanchez, Del RM, Wu O., et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001 ; 98: 4687-4692.
43. Lauritzen M., Skyhoj OT, Lassen NA, Paulson OB Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol 1983 ; 13: 633-641.
44. Lauritzen M. Pathophysiology of the migraine aura: the spreading depression theory. Brain 1994 ; 117 (Pt 1). 199-210.
45. Olesen J., Larsen B., Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981 ; 9: 344-352.
46. Olesen J., Lauritzen M., Tfelt-Hansen P., Henriksen L., Larsen B. Spreading cerebral oligemia in classical-and normal cerebral blood flow in common migraine. Headache 1982 ; 22: 242-248.
47. Olesen J., Friberg L., Olsen TS, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990 ; 28: 791-798.
48. Woods RP, Iacoboni M., Mazziotta JC Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994 ; 331: 1689-1692.
49. Wolff HG Headache and other head pain, 2 nd edn. Oxford: Oxford University Press, 1963.